Literature DB >> 15173019

Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.

Lars Dyrskjøt1, Mogens Kruhøffer, Thomas Thykjaer, Niels Marcussen, Jens L Jensen, Klaus Møller, Torben F Ørntoft.   

Abstract

The presence of carcinoma in situ (CIS) lesions in the urinary bladder is associated with a high risk of disease progression to a muscle invasive stage. In this study, we used microarray expression profiling to examine the gene expression patterns in superficial transitional cell carcinoma (sTCC) with surrounding CIS (13 patients), without surrounding CIS lesions (15 patients), and in muscle invasive carcinomas (mTCC; 13 patients). Hierarchical cluster analysis separated the sTCC samples according to the presence or absence of CIS in the surrounding urothelium. We identified a few gene clusters that contained genes with similar expression levels in transitional cell carcinoma (TCC) with surrounding CIS and invasive TCC. However, no close relationship between TCC with adjacent CIS and invasive TCC was observed using hierarchical cluster analysis. Expression profiling of a series of biopsies from normal urothelium and urothelium with CIS lesions from the same urinary bladder revealed that the gene expression found in sTCC with surrounding CIS is found also in CIS biopsies as well as in histologically normal samples adjacent to the CIS lesions. Furthermore, we also identified similar gene expression changes in mTCC samples. We used a supervised learning approach to build a 16-gene molecular CIS classifier. The classifier was able to classify sTCC samples according to the presence or absence of surrounding CIS with a high accuracy. This study demonstrates that a CIS gene expression signature is present not only in CIS biopsies but also in sTCC, mTCC, and, remarkably, in histologically normal urothelium from bladders with CIS. Identification of this expression signature could provide guidance for the selection of therapy and follow-up regimen in patients with early stage bladder cancer.

Entities:  

Mesh:

Year:  2004        PMID: 15173019     DOI: 10.1158/0008-5472.CAN-03-3620

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  202 in total

1.  PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells.

Authors:  Annalisa Carlucci; Monia Porpora; Corrado Garbi; Mario Galgani; Margherita Santoriello; Massimo Mascolo; Domenico di Lorenzo; Vincenzo Altieri; Maria Quarto; Luigi Terracciano; Max E Gottesman; Luigi Insabato; Antonio Feliciello
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.

Authors:  Neveen Said; Marta Sanchez-Carbayo; Steven C Smith; Dan Theodorescu
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

3.  Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer.

Authors:  Pang-Kuo Lo; Ji Shin Lee; Xiaohui Liang; Liangfeng Han; Tsuyoshi Mori; Mary Jo Fackler; Helen Sadik; Pedram Argani; Tej K Pandita; Saraswati Sukumar
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

4.  Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma.

Authors:  Nadia A Atai; Manju Bansal; Cheungh Lo; Joost Bosman; Wikky Tigchelaar; Klazien S Bosch; Ard Jonker; Philip C De Witt Hamer; Dirk Troost; Christopher A McCulloch; Vincent Everts; Cornelis J F Van Noorden; Jaro Sodek
Journal:  Immunology       Date:  2010-08-17       Impact factor: 7.397

Review 5.  The Oct1 transcription factor and epithelial malignancies: Old protein learns new tricks.

Authors:  Karina Vázquez-Arreguín; Dean Tantin
Journal:  Biochim Biophys Acta       Date:  2016-02-10

Review 6.  The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence.

Authors:  Benjamin A Mooso; Ruth L Vinall; Maria Mudryj; Stanley A Yap; Ralph W deVere White; Paramita M Ghosh
Journal:  J Urol       Date:  2014-08-23       Impact factor: 7.450

7.  Expression of cyclin d1 and its association with disease characteristics in bladder cancer.

Authors:  Pradeep Kumar Kopparapu; Stephen A Boorjian; Brian D Robinson; Martin Downes; Lorraine J Gudas; Nigel P Mongan; Jenny L Persson
Journal:  Anticancer Res       Date:  2013-12       Impact factor: 2.480

8.  Overexpression of atypical protein kinase C in HeLa cells facilitates macropinocytosis via Src activation.

Authors:  Ellen J Tisdale; Assia Shisheva; Cristina R Artalejo
Journal:  Cell Signal       Date:  2014-02-27       Impact factor: 4.315

9.  Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1α.

Authors:  Wei Zhao; Cunjie Chang; Yangyan Cui; Xiaozhi Zhao; Jun Yang; Lan Shen; Ji Zhou; Zhibo Hou; Zhen Zhang; Changxiao Ye; Donald Hasenmayer; Robert Perkins; Xiaojing Huang; Xin Yao; Like Yu; Ruimin Huang; Dianzheng Zhang; Hongqian Guo; Jun Yan
Journal:  J Biol Chem       Date:  2014-02-28       Impact factor: 5.157

10.  Revealing global regulatory perturbations across human cancers.

Authors:  Hani Goodarzi; Olivier Elemento; Saeed Tavazoie
Journal:  Mol Cell       Date:  2009-12-11       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.